GPBAR1 and Insulin resistance: Curcumin has demonstrated clinical efficacy in a 24-week randomized controlled trial in patients with nonalcoholic simple fatty liver disease, where supplementation reduced hepatic fat content, body weight, and insulin resistance while elevating circulating DCA levels, TGR5 expression, and GLP-1 secretion.